PI Perspective 25: Adefovir Warning

PI Perspective 25: Adefovir Warning

Project Inform - September, 1998

People taking the anti-HIV drug adefovir (Preveon®) for more than 20 weeks may be at higher risk for developing kidney toxicity due to accumulation of the drug in their blood, according to preliminary observations. Adefovir is a new type of reverse transcriptase inhibitor—called a nucleotide reverse transcriptase inhibitor—that is in large studies. It is also available through an expanded access program. People taking adefovir are now recommended to either reduce to a lower dose (from 120mg once a day to 60mg once a day) after being on the higher dose for 20 weeks and/or increase monitoring of serum creatinine levels, which are a measure of kidney function.

980901
PI980913

Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.

©1998. This document is copyrighted by Project Inform, 205 13th Street, #2001, San Francisco, CA 94103. Treatment Hotline: 800-822-7422 (toll-free) or 415-558-9051 (in the San Francisco Bay Area and internationally) All Project Inform materials may be reprinted and/or distributed without prior permission. However, reprints may not be edited and must include the following text: "From Project Inform, for more information contact the Project Inform National HIV/AIDS Treatment Hotline, 800-822-7422." For permission to edit any Project Inform material for further publication, contact David Evans at the Project Inform office.

Project Inform, established in 1985 as a national, non profit, community-based HIV/AIDS treatment information and advocacy organization, serves HIV-infected individuals, their care-givers, and their healthcare and service providers through its national, toll-free treatment hotline, the PI Perspective and other information publications, educational Town Meetings, on-line services and research and drug access advocacy programs. All information is available free of charge; donations are strongly encouraged. For more information, contact the Project Inform National HIV/AIDS Treatment Hotline. Email: web@projinf.org; Website: http://www.projinf.org.

The original of this article can be found at http://www.projinf.org/pub/25/newdrugs.html

This information is designed to support, not replace, the relationship that exists between you and your doctor.
©1998. AEGiS.